{
    "info": {
        "nct_id": "NCT05249114",
        "official_title": "Phase Ib Study of Cabozantinib in Combination With Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Progressive, Previously Treated Somatostatin Receptor 2 (SSTR2) Positive Neuroendocrine Tumors (NETs)",
        "inclusion_criteria": "1. Patients with unresectable, progressive, histologically well-differentiated neuroendocrine tumors of the fore-, mid-, or hindgut, including pancreas, or those with an unknown primary with target lesions overexpressing somatostatin receptors (Krenning 2, 3 or 4) on a SSTR PET.\n2. Patients must have previously received one or more lines of systemic therapy including somatostatin analogue therapy.\n3. Prior PRRT therapy is permitted up to a maximum of 4 standard doses. Enrollment of R-PRRT patients is permitted after initially 3 PRRT-naïve patients have been enrolled on protocol and if the minimum progression free survival (PFS) with initial PRRT therapy was ≥ 18 months from day 1, cycle 1 of PRRT to progression.\n4. ECOG 0-2.\n5. Recovery to baseline or ≤ Grade 1 (CTCAE v5.0) from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.\n6. Minimum 18 years or older.\n7. Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment:\n\n   1. Absolute neutrophil count (ANC) ≥ 1500/µL without granulocyte colony-stimulating factor support.\n   2. White blood cell count ≥ 2500/µL.\n   3. Platelets ≥ 100,000/µL without transfusion.\n   4. Hemoglobin ≥ 9 g/dL (≥ 90 g/L).\n   5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN with documented bone metastases.\n   6. Total bilirubin ≤ 1.5 x ULN (for patients with Gilbert's disease ≤ 3 x ULN).\n   7. Serum albumin ≥ 2.8 g/dl\n   8. (PT)/INR or partial thromboplastin time (PTT) test < 1.3 x the laboratory ULN\n   9. Serum creatinine ≤ 2.0 x ULN or estimated creatinine clearance ≥ 30 mL/min (≥ 0.5 mL/sec) using the Cockcroft-Gault equation:\n\n      Males: (140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72) Females: [(140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72)] × 0.85\n   10. Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol), or 24-h urine protein ≤ 1 g\n8. Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.\n9. Sexually active fertile participants and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment.\n10. Female participants of childbearing potential must not be pregnant at screening. Female participants are considered to be of childbearing potential unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes. In addition, females < 55 years-of-age must have a serum follicle stimulating (FSH) level > 40 mIU/mL to confirm menopause). Note: Documentation may include review of medical records, medical examinations, or medical history interview by study site.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Prior therapy with cabozantinib.\n2. Tumors with poorly differentiated or small cell histology.\n3. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.\n4. Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.\n5. Radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Participants with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n6. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis). Participants must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible participants must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.\n7. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:\n\n   1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n   2. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n8. The participant has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n   a. Cardiovascular disorders: i. Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.\n\n   ii. Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.\n\n   iii. Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose of study treatment.\n   1. Participants with a diagnosis of incidental, subsegmental PE or DVT within 6 months are allowed if stable, asymptomatic, and treated with a stable dose of permitted anticoagulation (see exclusion criterion #6) for at least 1 week before first dose of study treatment.\n   2. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:\n\n   i. The participant has evidence of tumor invading into the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), active diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.\n\n   ii. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment.\n\n   iii. Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.\n9. Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment.\n10. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.\n11. Other clinically significant disorders that would preclude safe study participation.\n\n    1. Serious non-healing wound/ulcer/bone fracture.\n    2. Uncompensated/symptomatic hypothyroidism.\n    3. Moderate to severe hepatic impairment (Child-Pugh B or C).\n12. Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment. Minor surgeries within 10 days before first dose of study treatment. Participants must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Participants with clinically relevant ongoing complications from prior surgery are not eligible.\n13. Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment [add reference for Fridericia formula].\n\n    Note: If a single ECG shows a QTcF with an absolute value > 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.\n14. Pregnant or lactating females.\n15. Inability to swallow tablets.\n16. Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n17. Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "8. Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.",
                "criterions": [
                    {
                        "exact_snippets": "Capable of understanding and complying with the protocol requirements",
                        "criterion": "ability to understand and comply with protocol requirements",
                        "requirement": {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must have signed the informed consent document",
                        "criterion": "informed consent document",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Capable of understanding and complying with the protocol requirements",
                        "criterion": "ability to understand and comply with protocol requirements",
                        "requirement": {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must have signed the informed consent document",
                        "criterion": "informed consent document",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Males: (140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72) Females: [(140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72)] × 0.85",
                "criterions": [
                    {
                        "exact_snippets": "Males: (140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72)",
                        "criterion": "creatinine clearance (Cockcroft-Gault formula for males)",
                        "requirement": {
                            "requirement_type": "calculation",
                            "expected_value": "(140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72)"
                        }
                    },
                    {
                        "exact_snippets": "Females: [(140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72)] × 0.85",
                        "criterion": "creatinine clearance (Cockcroft-Gault formula for females)",
                        "requirement": {
                            "requirement_type": "calculation",
                            "expected_value": "[(140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72)] × 0.85"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Males: (140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72)",
                        "criterion": "creatinine clearance (Cockcroft-Gault formula for males)",
                        "requirement": {
                            "requirement_type": "calculation",
                            "expected_value": "(140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72)"
                        }
                    },
                    {
                        "exact_snippets": "Females: [(140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72)] × 0.85",
                        "criterion": "creatinine clearance (Cockcroft-Gault formula for females)",
                        "requirement": {
                            "requirement_type": "calculation",
                            "expected_value": "[(140 - age) x weight (kg)/(serum creatinine [mg/dL] × 72)] × 0.85"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Total bilirubin ≤ 1.5 x ULN (for patients with Gilbert's disease ≤ 3 x ULN).",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 x ULN (for patients with Gilbert's disease ≤ 3 x ULN)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "for patients with Gilbert's disease ≤ 3 x ULN",
                        "criterion": "total bilirubin in patients with Gilbert's disease",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "for patients with Gilbert's disease ≤ 3 x ULN",
                    "criterion": "total bilirubin in patients with Gilbert's disease",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 3,
                                    "unit": "x ULN"
                                }
                            ]
                        }
                    }
                },
                "then_criteria": null,
                "else_criteria": {
                    "exact_snippets": "Total bilirubin ≤ 1.5 x ULN (for patients with Gilbert's disease ≤ 3 x ULN)",
                    "criterion": "total bilirubin",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 1.5,
                                    "unit": "x ULN"
                                }
                            ]
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "7. Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment:",
                "criterions": [
                    {
                        "exact_snippets": "Adequate organ and marrow function",
                        "criterion": "organ and marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate organ and marrow function",
                        "criterion": "organ and marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Minimum 18 years or older.",
                "criterions": [
                    {
                        "exact_snippets": "Minimum 18 years or older.",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Minimum 18 years or older.",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Recovery to baseline or ≤ Grade 1 (CTCAE v5.0) from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Recovery to baseline or ≤ Grade 1 (CTCAE v5.0) from toxicities related to any prior treatments",
                        "criterion": "toxicities related to any prior treatments",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE v5.0 grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Recovery to baseline or ≤ Grade 1 (CTCAE v5.0) from toxicities related to any prior treatments",
                        "criterion": "toxicities related to any prior treatments",
                        "requirement": {
                            "requirement_type": "recovery_status",
                            "expected_value": "baseline"
                        }
                    },
                    {
                        "exact_snippets": "unless AE(s) are clinically nonsignificant and/or stable on supportive therapy",
                        "criterion": "adverse events (AEs) related to prior treatments",
                        "requirement": {
                            "requirement_type": "clinical_significance",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "unless AE(s) are clinically nonsignificant and/or stable on supportive therapy",
                        "criterion": "adverse events (AEs) related to prior treatments",
                        "requirement": {
                            "requirement_type": "stability_on_supportive_therapy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "Recovery to baseline or ≤ Grade 1 (CTCAE v5.0) from toxicities related to any prior treatments",
                                        "criterion": "toxicities related to any prior treatments",
                                        "requirement": {
                                            "requirement_type": "severity",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 1,
                                                "unit": "CTCAE v5.0 grade"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Recovery to baseline or ≤ Grade 1 (CTCAE v5.0) from toxicities related to any prior treatments",
                                        "criterion": "toxicities related to any prior treatments",
                                        "requirement": {
                                            "requirement_type": "recovery_status",
                                            "expected_value": "baseline"
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "unless AE(s) are clinically nonsignificant and/or stable on supportive therapy",
                                "criterion": "adverse events (AEs) related to prior treatments",
                                "requirement": {
                                    "requirement_type": "clinical_significance",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "unless AE(s) are clinically nonsignificant and/or stable on supportive therapy",
                                "criterion": "adverse events (AEs) related to prior treatments",
                                "requirement": {
                                    "requirement_type": "stability_on_supportive_therapy",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol), or 24-h urine protein ≤ 1 g",
                "criterions": [
                    {
                        "exact_snippets": "Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol)",
                        "criterion": "urine protein/creatinine ratio (UPCR)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "mg/mg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol)",
                        "criterion": "urine protein/creatinine ratio (UPCR)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 113.2,
                                "unit": "mg/mmol"
                            }
                        }
                    },
                    {
                        "exact_snippets": "24-h urine protein ≤ 1 g",
                        "criterion": "24-hour urine protein",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "g"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol)",
                                "criterion": "urine protein/creatinine ratio (UPCR)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "mg/mg"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol)",
                                "criterion": "urine protein/creatinine ratio (UPCR)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 113.2,
                                        "unit": "mg/mmol"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "24-h urine protein ≤ 1 g",
                        "criterion": "24-hour urine protein",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "g"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Patients must have previously received one or more lines of systemic therapy including somatostatin analogue therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Patients must have previously received one or more lines of systemic therapy",
                        "criterion": "prior systemic therapy",
                        "requirement": {
                            "requirement_type": "number of lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients must have previously received one or more lines of systemic therapy",
                        "criterion": "prior systemic therapy",
                        "requirement": {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including somatostatin analogue therapy",
                        "criterion": "prior somatostatin analogue therapy",
                        "requirement": {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients must have previously received one or more lines of systemic therapy",
                        "criterion": "prior systemic therapy",
                        "requirement": {
                            "requirement_type": "number of lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients must have previously received one or more lines of systemic therapy",
                        "criterion": "prior systemic therapy",
                        "requirement": {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including somatostatin analogue therapy",
                        "criterion": "prior somatostatin analogue therapy",
                        "requirement": {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN with documented bone metastases.",
                "criterions": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 3 x upper limit of normal (ULN)",
                        "criterion": "alanine aminotransferase (ALT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "aspartate aminotransferase (AST) ... ≤ 3 x upper limit of normal (ULN)",
                        "criterion": "aspartate aminotransferase (AST)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN with documented bone metastases.",
                        "criterion": "alkaline phosphatase (ALP)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN with documented bone metastases.",
                        "criterion": "alkaline phosphatase (ALP)",
                        "requirement": {
                            "requirement_type": "quantity with bone metastases",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 3 x upper limit of normal (ULN)",
                        "criterion": "alanine aminotransferase (ALT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "aspartate aminotransferase (AST) ... ≤ 3 x upper limit of normal (ULN)",
                        "criterion": "aspartate aminotransferase (AST)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "condition": {
                            "exact_snippets": "alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN with documented bone metastases.",
                            "criterion": "alkaline phosphatase (ALP)",
                            "requirement": {
                                "requirement_type": "quantity with bone metastases",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 5,
                                    "unit": "x ULN"
                                }
                            }
                        },
                        "then_criteria": null,
                        "else_criteria": {
                            "exact_snippets": "alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN with documented bone metastases.",
                            "criterion": "alkaline phosphatase (ALP)",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 3,
                                    "unit": "x ULN"
                                }
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Serum creatinine ≤ 2.0 x ULN or estimated creatinine clearance ≥ 30 mL/min (≥ 0.5 mL/sec) using the Cockcroft-Gault equation:",
                "criterions": [
                    {
                        "exact_snippets": "Serum creatinine ≤ 2.0 x ULN",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "estimated creatinine clearance ≥ 30 mL/min (≥ 0.5 mL/sec) using the Cockcroft-Gault equation",
                        "criterion": "estimated creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "estimated creatinine clearance ≥ 30 mL/min (≥ 0.5 mL/sec) using the Cockcroft-Gault equation",
                        "criterion": "estimated creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault equation"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Serum creatinine ≤ 2.0 x ULN",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "estimated creatinine clearance ≥ 30 mL/min (≥ 0.5 mL/sec) using the Cockcroft-Gault equation",
                                "criterion": "estimated creatinine clearance",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "mL/min"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "estimated creatinine clearance ≥ 30 mL/min (≥ 0.5 mL/sec) using the Cockcroft-Gault equation",
                                "criterion": "estimated creatinine clearance",
                                "requirement": {
                                    "requirement_type": "calculation method",
                                    "expected_value": "Cockcroft-Gault equation"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. ECOG 0-2.",
                "criterions": [
                    {
                        "exact_snippets": "ECOG 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Platelets ≥ 100,000/µL without transfusion.",
                "criterions": [
                    {
                        "exact_snippets": "Platelets ≥ 100,000/µL without transfusion",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/µL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelets ≥ 100,000/µL without transfusion",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "transfusion support",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelets ≥ 100,000/µL without transfusion",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/µL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelets ≥ 100,000/µL without transfusion",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "transfusion support",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. White blood cell count ≥ 2500/µL.",
                "criterions": [
                    {
                        "exact_snippets": "White blood cell count ≥ 2500/µL",
                        "criterion": "white blood cell count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2500,
                                "unit": "/µL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "White blood cell count ≥ 2500/µL",
                        "criterion": "white blood cell count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2500,
                                "unit": "/µL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. (PT)/INR or partial thromboplastin time (PTT) test < 1.3 x the laboratory ULN",
                "criterions": [
                    {
                        "exact_snippets": "(PT)/INR ... < 1.3 x the laboratory ULN",
                        "criterion": "prothrombin time/international normalized ratio (PT/INR)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.3,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "partial thromboplastin time (PTT) test < 1.3 x the laboratory ULN",
                        "criterion": "partial thromboplastin time (PTT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.3,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "(PT)/INR ... < 1.3 x the laboratory ULN",
                        "criterion": "prothrombin time/international normalized ratio (PT/INR)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.3,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "partial thromboplastin time (PTT) test < 1.3 x the laboratory ULN",
                        "criterion": "partial thromboplastin time (PTT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.3,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "a. Cardiovascular disorders: i. Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.",
                "criterions": [
                    {
                        "exact_snippets": "Congestive heart failure New York Heart Association Class 3 or 4",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "NYHA class"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "unstable angina pectoris",
                        "criterion": "angina pectoris",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    },
                    {
                        "exact_snippets": "serious cardiac arrhythmias",
                        "criterion": "cardiac arrhythmias",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Congestive heart failure New York Heart Association Class 3 or 4",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "NYHA class"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "unstable angina pectoris",
                        "criterion": "angina pectoris",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    },
                    {
                        "exact_snippets": "serious cardiac arrhythmias",
                        "criterion": "cardiac arrhythmias",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "15. Inability to swallow tablets.",
                "criterions": [
                    {
                        "exact_snippets": "Inability to swallow tablets",
                        "criterion": "ability to swallow tablets",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Inability to swallow tablets",
                        "criterion": "ability to swallow tablets",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Clinically significant hematuria",
                        "criterion": "hematuria",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant ... hematemesis",
                        "criterion": "hematemesis",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant ... hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood",
                        "criterion": "hemoptysis",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant ... hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood",
                        "criterion": "hemoptysis",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "ml"
                            }
                        }
                    },
                    {
                        "exact_snippets": "other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment",
                        "criterion": "significant bleeding",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": "within 12 weeks before first dose of study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Clinically significant hematuria",
                                "criterion": "hematuria",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "clinically significant"
                                }
                            },
                            {
                                "exact_snippets": "Clinically significant ... hematemesis",
                                "criterion": "hematemesis",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "clinically significant"
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Clinically significant ... hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood",
                                        "criterion": "hemoptysis",
                                        "requirement": {
                                            "requirement_type": "severity",
                                            "expected_value": "clinically significant"
                                        }
                                    },
                                    {
                                        "exact_snippets": "Clinically significant ... hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood",
                                        "criterion": "hemoptysis",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 2.5,
                                                "unit": "ml"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "exact_snippets": "other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment",
                        "criterion": "significant bleeding",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": "within 12 weeks before first dose of study treatment"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Tumors with poorly differentiated or small cell histology.",
                "criterions": [
                    {
                        "exact_snippets": "Tumors with poorly differentiated ... histology",
                        "criterion": "tumor histology",
                        "requirement": {
                            "requirement_type": "differentiation",
                            "expected_value": "poorly differentiated"
                        }
                    },
                    {
                        "exact_snippets": "Tumors with ... small cell histology",
                        "criterion": "tumor histology",
                        "requirement": {
                            "requirement_type": "cell type",
                            "expected_value": "small cell"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Tumors with poorly differentiated ... histology",
                        "criterion": "tumor histology",
                        "requirement": {
                            "requirement_type": "differentiation",
                            "expected_value": "poorly differentiated"
                        }
                    },
                    {
                        "exact_snippets": "Tumors with ... small cell histology",
                        "criterion": "tumor histology",
                        "requirement": {
                            "requirement_type": "cell type",
                            "expected_value": "small cell"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Other clinically significant disorders that would preclude safe study participation.",
                "criterions": [
                    {
                        "exact_snippets": "Other clinically significant disorders that would preclude safe study participation.",
                        "criterion": "clinically significant disorders",
                        "requirement": {
                            "requirement_type": "impact on study participation",
                            "expected_value": "would preclude safe study participation"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Other clinically significant disorders that would preclude safe study participation.",
                        "criterion": "clinically significant disorders",
                        "requirement": {
                            "requirement_type": "impact on study participation",
                            "expected_value": "would preclude safe study participation"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Prior therapy with cabozantinib.",
                "criterions": [
                    {
                        "exact_snippets": "Prior therapy with cabozantinib.",
                        "criterion": "cabozantinib therapy",
                        "requirement": {
                            "requirement_type": "history of prior therapy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Prior therapy with cabozantinib.",
                    "criterion": "cabozantinib therapy",
                    "requirement": {
                        "requirement_type": "history of prior therapy",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "iii. Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.",
                        "criterion": "intra-abdominal abscess",
                        "requirement": {
                            "requirement_type": "healing status",
                            "expected_value": "complete healing"
                        }
                    },
                    {
                        "exact_snippets": "Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.",
                        "criterion": "intra-abdominal abscess",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.",
                        "criterion": "intra-abdominal abscess",
                        "requirement": {
                            "requirement_type": "healing status",
                            "expected_value": "complete healing"
                        }
                    },
                    {
                        "exact_snippets": "Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.",
                        "criterion": "intra-abdominal abscess",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Uncompensated/symptomatic hypothyroidism.",
                "criterions": [
                    {
                        "exact_snippets": "Uncompensated/symptomatic hypothyroidism",
                        "criterion": "hypothyroidism",
                        "requirement": {
                            "requirement_type": "compensation status",
                            "expected_value": "uncompensated"
                        }
                    },
                    {
                        "exact_snippets": "Uncompensated/symptomatic hypothyroidism",
                        "criterion": "hypothyroidism",
                        "requirement": {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Uncompensated/symptomatic hypothyroidism",
                        "criterion": "hypothyroidism",
                        "requirement": {
                            "requirement_type": "compensation status",
                            "expected_value": "uncompensated"
                        }
                    },
                    {
                        "exact_snippets": "Uncompensated/symptomatic hypothyroidism",
                        "criterion": "hypothyroidism",
                        "requirement": {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.",
                        "criterion": "small molecule kinase inhibitor receipt",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks before first dose of study treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.",
                        "criterion": "small molecule kinase inhibitor receipt",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.",
                                "criterion": "small molecule kinase inhibitor receipt",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.",
                                "criterion": "small molecule kinase inhibitor receipt",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks before first dose of study treatment"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.",
                "criterions": [
                    {
                        "exact_snippets": "Cavitating pulmonary lesion(s)",
                        "criterion": "cavitating pulmonary lesion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known endotracheal or endobronchial disease manifestation",
                        "criterion": "endotracheal or endobronchial disease manifestation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Cavitating pulmonary lesion(s)",
                        "criterion": "cavitating pulmonary lesion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known endotracheal or endobronchial disease manifestation",
                        "criterion": "endotracheal or endobronchial disease manifestation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "16. Previously identified allergy or hypersensitivity to components of the study treatment formulations.",
                "criterions": [
                    {
                        "exact_snippets": "Previously identified allergy or hypersensitivity to components of the study treatment formulations.",
                        "criterion": "allergy or hypersensitivity to components of the study treatment formulations",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Previously identified allergy or hypersensitivity to components of the study treatment formulations.",
                    "criterion": "allergy or hypersensitivity to components of the study treatment formulations",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Serious non-healing wound/ulcer/bone fracture.",
                "criterions": [
                    {
                        "exact_snippets": "Serious non-healing wound",
                        "criterion": "wound",
                        "requirement": {
                            "requirement_type": "healing status",
                            "expected_value": "serious non-healing"
                        }
                    },
                    {
                        "exact_snippets": "Serious non-healing ... ulcer",
                        "criterion": "ulcer",
                        "requirement": {
                            "requirement_type": "healing status",
                            "expected_value": "serious non-healing"
                        }
                    },
                    {
                        "exact_snippets": "Serious non-healing ... bone fracture",
                        "criterion": "bone fracture",
                        "requirement": {
                            "requirement_type": "healing status",
                            "expected_value": "serious non-healing"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Serious non-healing wound",
                        "criterion": "wound",
                        "requirement": {
                            "requirement_type": "healing status",
                            "expected_value": "serious non-healing"
                        }
                    },
                    {
                        "exact_snippets": "Serious non-healing ... ulcer",
                        "criterion": "ulcer",
                        "requirement": {
                            "requirement_type": "healing status",
                            "expected_value": "serious non-healing"
                        }
                    },
                    {
                        "exact_snippets": "Serious non-healing ... bone fracture",
                        "criterion": "bone fracture",
                        "requirement": {
                            "requirement_type": "healing status",
                            "expected_value": "serious non-healing"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:",
                "criterions": [
                    {
                        "exact_snippets": "Gastrointestinal (GI) disorders",
                        "criterion": "gastrointestinal disorders",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "associated with a high risk of perforation",
                        "criterion": "risk of gastrointestinal perforation",
                        "requirement": {
                            "requirement_type": "risk level",
                            "expected_value": "high"
                        }
                    },
                    {
                        "exact_snippets": "associated with a high risk of ... fistula formation",
                        "criterion": "risk of gastrointestinal fistula formation",
                        "requirement": {
                            "requirement_type": "risk level",
                            "expected_value": "high"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Gastrointestinal (GI) disorders",
                                "criterion": "gastrointestinal disorders",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "associated with a high risk of perforation",
                                        "criterion": "risk of gastrointestinal perforation",
                                        "requirement": {
                                            "requirement_type": "risk level",
                                            "expected_value": "high"
                                        }
                                    },
                                    {
                                        "exact_snippets": "associated with a high risk of ... fistula formation",
                                        "criterion": "risk of gastrointestinal fistula formation",
                                        "requirement": {
                                            "requirement_type": "risk level",
                                            "expected_value": "high"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Note: If a single ECG shows a QTcF with an absolute value > 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.",
                "criterions": [
                    {
                        "exact_snippets": "a single ECG shows a QTcF with an absolute value > 500 ms ... the average of these three consecutive results for QTcF will be used to determine eligibility",
                        "criterion": "QTcF interval",
                        "requirement": {
                            "requirement_type": "measurement method",
                            "expected_value": "average of three consecutive ECGs"
                        }
                    },
                    {
                        "exact_snippets": "a single ECG shows a QTcF with an absolute value > 500 ms ... the average of these three consecutive results for QTcF will be used to determine eligibility",
                        "criterion": "QTcF interval",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 500,
                                "unit": "ms"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "a single ECG shows a QTcF with an absolute value > 500 ms ... the average of these three consecutive results for QTcF will be used to determine eligibility",
                                "criterion": "QTcF interval",
                                "requirement": {
                                    "requirement_type": "measurement method",
                                    "expected_value": "average of three consecutive ECGs"
                                }
                            },
                            {
                                "exact_snippets": "a single ECG shows a QTcF with an absolute value > 500 ms ... the average of these three consecutive results for QTcF will be used to determine eligibility",
                                "criterion": "QTcF interval",
                                "requirement": {
                                    "requirement_type": "value",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 500,
                                        "unit": "ms"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).",
                "criterions": [
                    {
                        "exact_snippets": "Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines)",
                        "criterion": "aspirin use",
                        "requirement": {
                            "requirement_type": "purpose",
                            "expected_value": "cardio-protection"
                        }
                    },
                    {
                        "exact_snippets": "Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines)",
                        "criterion": "aspirin use",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": "low-dose"
                        }
                    },
                    {
                        "exact_snippets": "Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines)",
                        "criterion": "aspirin use",
                        "requirement": {
                            "requirement_type": "use_type",
                            "expected_value": "prophylactic"
                        }
                    },
                    {
                        "exact_snippets": "low-dose low molecular weight heparins (LMWH)",
                        "criterion": "low molecular weight heparin (LMWH) use",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": "low-dose"
                        }
                    },
                    {
                        "exact_snippets": "low-dose low molecular weight heparins (LMWH)",
                        "criterion": "low molecular weight heparin (LMWH) use",
                        "requirement": {
                            "requirement_type": "use_type",
                            "expected_value": "prophylactic"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines)",
                                "criterion": "aspirin use",
                                "requirement": {
                                    "requirement_type": "purpose",
                                    "expected_value": "cardio-protection"
                                }
                            },
                            {
                                "exact_snippets": "Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines)",
                                "criterion": "aspirin use",
                                "requirement": {
                                    "requirement_type": "dose",
                                    "expected_value": "low-dose"
                                }
                            },
                            {
                                "exact_snippets": "Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines)",
                                "criterion": "aspirin use",
                                "requirement": {
                                    "requirement_type": "use_type",
                                    "expected_value": "prophylactic"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "low-dose low molecular weight heparins (LMWH)",
                                "criterion": "low molecular weight heparin (LMWH) use",
                                "requirement": {
                                    "requirement_type": "dose",
                                    "expected_value": "low-dose"
                                }
                            },
                            {
                                "exact_snippets": "low-dose low molecular weight heparins (LMWH)",
                                "criterion": "low molecular weight heparin (LMWH) use",
                                "requirement": {
                                    "requirement_type": "use_type",
                                    "expected_value": "prophylactic"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "ii. Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.",
                        "criterion": "blood pressure",
                        "requirement": {
                            "requirement_type": "systolic pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 140,
                                "unit": "mm Hg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.",
                        "criterion": "blood pressure",
                        "requirement": {
                            "requirement_type": "diastolic pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "mm Hg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.",
                        "criterion": "blood pressure",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "despite optimal antihypertensive treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.",
                                        "criterion": "blood pressure",
                                        "requirement": {
                                            "requirement_type": "systolic pressure",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 140,
                                                "unit": "mm Hg"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.",
                                        "criterion": "blood pressure",
                                        "requirement": {
                                            "requirement_type": "treatment status",
                                            "expected_value": "despite optimal antihypertensive treatment"
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.",
                                        "criterion": "blood pressure",
                                        "requirement": {
                                            "requirement_type": "diastolic pressure",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 90,
                                                "unit": "mm Hg"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.",
                                        "criterion": "blood pressure",
                                        "requirement": {
                                            "requirement_type": "treatment status",
                                            "expected_value": "despite optimal antihypertensive treatment"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant anticoagulation with coumarin agents (e.g., warfarin)",
                        "criterion": "concomitant anticoagulation with coumarin agents",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant anticoagulation with ... direct thrombin inhibitors (e.g., dabigatran)",
                        "criterion": "concomitant anticoagulation with direct thrombin inhibitors",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant anticoagulation with ... direct factor Xa inhibitor betrixaban",
                        "criterion": "concomitant anticoagulation with direct factor Xa inhibitor betrixaban",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant anticoagulation with ... platelet inhibitors (e.g., clopidogrel)",
                        "criterion": "concomitant anticoagulation with platelet inhibitors",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Concomitant anticoagulation with coumarin agents (e.g., warfarin)",
                        "criterion": "concomitant anticoagulation with coumarin agents",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant anticoagulation with ... direct thrombin inhibitors (e.g., dabigatran)",
                        "criterion": "concomitant anticoagulation with direct thrombin inhibitors",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant anticoagulation with ... direct factor Xa inhibitor betrixaban",
                        "criterion": "concomitant anticoagulation with direct factor Xa inhibitor betrixaban",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant anticoagulation with ... platelet inhibitors (e.g., clopidogrel)",
                        "criterion": "concomitant anticoagulation with platelet inhibitors",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment. Minor surgeries within 10 days before first dose of study treatment. Participants must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Participants with clinically relevant ongoing complications from prior surgery are not eligible.",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery ... within 2 weeks before first dose of study treatment",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Minor surgeries within 10 days before first dose of study treatment",
                        "criterion": "minor surgery",
                        "requirement": {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Participants must have complete wound healing from major surgery or minor surgery before first dose of study treatment",
                        "criterion": "wound healing from surgery",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "complete"
                        }
                    },
                    {
                        "exact_snippets": "Participants with clinically relevant ongoing complications from prior surgery are not eligible",
                        "criterion": "clinically relevant ongoing complications from prior surgery",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Major surgery ... within 2 weeks before first dose of study treatment",
                            "criterion": "major surgery",
                            "requirement": {
                                "requirement_type": "time since surgery",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 2,
                                    "unit": "weeks"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Minor surgeries within 10 days before first dose of study treatment",
                            "criterion": "minor surgery",
                            "requirement": {
                                "requirement_type": "time since surgery",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 10,
                                    "unit": "days"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Participants must have complete wound healing from major surgery or minor surgery before first dose of study treatment",
                            "criterion": "wound healing from surgery",
                            "requirement": {
                                "requirement_type": "status",
                                "expected_value": "complete"
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Participants with clinically relevant ongoing complications from prior surgery are not eligible",
                            "criterion": "clinically relevant ongoing complications from prior surgery",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "ii. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Abdominal fistula ... within 6 months before first dose of study treatment",
                        "criterion": "abdominal fistula",
                        "requirement": {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "GI perforation ... within 6 months before first dose of study treatment",
                        "criterion": "gastrointestinal perforation",
                        "requirement": {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "bowel obstruction ... within 6 months before first dose of study treatment",
                        "criterion": "bowel obstruction",
                        "requirement": {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "intra-abdominal abscess within 6 months before first dose of study treatment",
                        "criterion": "intra-abdominal abscess",
                        "requirement": {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Abdominal fistula ... within 6 months before first dose of study treatment",
                        "criterion": "abdominal fistula",
                        "requirement": {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "GI perforation ... within 6 months before first dose of study treatment",
                        "criterion": "gastrointestinal perforation",
                        "requirement": {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "bowel obstruction ... within 6 months before first dose of study treatment",
                        "criterion": "bowel obstruction",
                        "requirement": {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "intra-abdominal abscess within 6 months before first dose of study treatment",
                        "criterion": "intra-abdominal abscess",
                        "requirement": {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Participants with clinically relevant ongoing complications from prior radiation therapy are not eligible.",
                "criterions": [
                    {
                        "exact_snippets": "Radiation therapy for bone metastasis within 2 weeks before first dose of study treatment",
                        "criterion": "radiation therapy for bone metastasis",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "any other radiation therapy within 4 weeks before first dose of study treatment",
                        "criterion": "other radiation therapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Systemic treatment with radionuclides within 6 weeks before first dose of study treatment",
                        "criterion": "systemic treatment with radionuclides",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "clinically relevant ongoing complications from prior radiation therapy",
                        "criterion": "ongoing complications from prior radiation therapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Radiation therapy for bone metastasis within 2 weeks before first dose of study treatment",
                            "criterion": "radiation therapy for bone metastasis",
                            "requirement": {
                                "requirement_type": "time since last treatment",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 2,
                                    "unit": "weeks"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "any other radiation therapy within 4 weeks before first dose of study treatment",
                            "criterion": "other radiation therapy",
                            "requirement": {
                                "requirement_type": "time since last treatment",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 4,
                                    "unit": "weeks"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Systemic treatment with radionuclides within 6 weeks before first dose of study treatment",
                            "criterion": "systemic treatment with radionuclides",
                            "requirement": {
                                "requirement_type": "time since last treatment",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 6,
                                    "unit": "weeks"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "clinically relevant ongoing complications from prior radiation therapy",
                            "criterion": "ongoing complications from prior radiation therapy",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. The participant has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:",
                "criterions": [
                    {
                        "exact_snippets": "uncontrolled, significant intercurrent or recent illness",
                        "criterion": "intercurrent or recent illness",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled, significant intercurrent or recent illness",
                        "criterion": "intercurrent or recent illness",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "uncontrolled, significant intercurrent or recent illness",
                        "criterion": "intercurrent or recent illness",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled, significant intercurrent or recent illness",
                        "criterion": "intercurrent or recent illness",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "iii. Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Stroke (including transient ischemic attack [TIA]) ... within 6 months before first dose of study treatment.",
                        "criterion": "stroke (including transient ischemic attack [TIA])",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before first dose of study treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction (MI) ... within 6 months before first dose of study treatment.",
                        "criterion": "myocardial infarction (MI)",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before first dose of study treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "other ischemic event ... within 6 months before first dose of study treatment.",
                        "criterion": "other ischemic event",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before first dose of study treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) ... within 6 months before first dose of study treatment.",
                        "criterion": "thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism)",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before first dose of study treatment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Stroke (including transient ischemic attack [TIA]) ... within 6 months before first dose of study treatment.",
                        "criterion": "stroke (including transient ischemic attack [TIA])",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before first dose of study treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction (MI) ... within 6 months before first dose of study treatment.",
                        "criterion": "myocardial infarction (MI)",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before first dose of study treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "other ischemic event ... within 6 months before first dose of study treatment.",
                        "criterion": "other ischemic event",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before first dose of study treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) ... within 6 months before first dose of study treatment.",
                        "criterion": "thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism)",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before first dose of study treatment"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment [add reference for Fridericia formula].",
                "criterions": [
                    {
                        "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment",
                        "criterion": "corrected QT interval (QTcF)",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Fridericia formula"
                        }
                    },
                    {
                        "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment",
                        "criterion": "corrected QT interval (QTcF)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "ms"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment",
                        "criterion": "corrected QT interval (QTcF)",
                        "requirement": {
                            "requirement_type": "measurement method",
                            "expected_value": "electrocardiogram (ECG)"
                        }
                    },
                    {
                        "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment",
                        "criterion": "corrected QT interval (QTcF)",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 14 days before first dose of study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment",
                        "criterion": "corrected QT interval (QTcF)",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Fridericia formula"
                        }
                    },
                    {
                        "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment",
                        "criterion": "corrected QT interval (QTcF)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "ms"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment",
                        "criterion": "corrected QT interval (QTcF)",
                        "requirement": {
                            "requirement_type": "measurement method",
                            "expected_value": "electrocardiogram (ECG)"
                        }
                    },
                    {
                        "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment",
                        "criterion": "corrected QT interval (QTcF)",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 14 days before first dose of study treatment"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. Pregnant or lactating females.",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant ... females",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "lactating females",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Pregnant ... females",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "lactating females",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "i. The participant has evidence of tumor invading into the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), active diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.",
                "criterions": [
                    {
                        "exact_snippets": "evidence of tumor invading into the GI tract",
                        "criterion": "tumor invasion into GI tract",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active peptic ulcer disease",
                        "criterion": "peptic ulcer disease",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "inflammatory bowel disease (e.g., Crohn's disease)",
                        "criterion": "inflammatory bowel disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active diverticulitis",
                        "criterion": "diverticulitis",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "cholecystitis",
                        "criterion": "cholecystitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "symptomatic cholangitis",
                        "criterion": "cholangitis",
                        "requirement": {
                            "requirement_type": "symptoms",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "appendicitis",
                        "criterion": "appendicitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "acute pancreatitis",
                        "criterion": "pancreatitis",
                        "requirement": {
                            "requirement_type": "acuteness",
                            "expected_value": "acute"
                        }
                    },
                    {
                        "exact_snippets": "acute obstruction of the pancreatic duct or common bile duct",
                        "criterion": "obstruction of pancreatic duct or common bile duct",
                        "requirement": {
                            "requirement_type": "acuteness",
                            "expected_value": "acute"
                        }
                    },
                    {
                        "exact_snippets": "gastric outlet obstruction",
                        "criterion": "gastric outlet obstruction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "evidence of tumor invading into the GI tract",
                        "criterion": "tumor invasion into GI tract",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active peptic ulcer disease",
                        "criterion": "peptic ulcer disease",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "inflammatory bowel disease (e.g., Crohn's disease)",
                        "criterion": "inflammatory bowel disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active diverticulitis",
                        "criterion": "diverticulitis",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "cholecystitis",
                        "criterion": "cholecystitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "symptomatic cholangitis",
                        "criterion": "cholangitis",
                        "requirement": {
                            "requirement_type": "symptoms",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "appendicitis",
                        "criterion": "appendicitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "acute pancreatitis",
                        "criterion": "pancreatitis",
                        "requirement": {
                            "requirement_type": "acuteness",
                            "expected_value": "acute"
                        }
                    },
                    {
                        "exact_snippets": "acute obstruction of the pancreatic duct or common bile duct",
                        "criterion": "obstruction of pancreatic duct or common bile duct",
                        "requirement": {
                            "requirement_type": "acuteness",
                            "expected_value": "acute"
                        }
                    },
                    {
                        "exact_snippets": "gastric outlet obstruction",
                        "criterion": "gastric outlet obstruction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "4. Hemoglobin ≥ 9 g/dL (≥ 90 g/L).",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin ≥ 9 g/dL (≥ 90 g/L)",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hemoglobin ≥ 9 g/dL (≥ 90 g/L)",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "g/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin \u001e 9 g/dL (\u001e 90 g/L)",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hemoglobin \u001e 9 g/dL (\u001e 90 g/L)",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "g/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Prior PRRT therapy is permitted up to a maximum of 4 standard doses. Enrollment of R-PRRT patients is permitted after initially 3 PRRT-naïve patients have been enrolled on protocol and if the minimum progression free survival (PFS) with initial PRRT therapy was ≥ 18 months from day 1, cycle 1 of PRRT to progression.",
                "criterions": [
                    {
                        "exact_snippets": "Prior PRRT therapy is permitted up to a maximum of 4 standard doses",
                        "criterion": "prior PRRT therapy",
                        "requirement": {
                            "requirement_type": "maximum number of standard doses",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "standard doses"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Enrollment of R-PRRT patients is permitted after initially 3 PRRT-naïve patients have been enrolled on protocol",
                        "criterion": "enrollment of R-PRRT patients",
                        "requirement": {
                            "requirement_type": "enrollment sequence",
                            "expected_value": "after 3 PRRT-naïve patients enrolled"
                        }
                    },
                    {
                        "exact_snippets": "minimum progression free survival (PFS) with initial PRRT therapy was ≥ 18 months from day 1, cycle 1 of PRRT to progression",
                        "criterion": "progression free survival (PFS) with initial PRRT therapy",
                        "requirement": {
                            "requirement_type": "minimum duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Prior PRRT therapy is permitted up to a maximum of 4 standard doses",
                                "criterion": "prior PRRT therapy",
                                "requirement": {
                                    "requirement_type": "maximum number of standard doses",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "standard doses"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "enrollment of R-PRRT patients is permitted after initially 3 PRRT-naïve patients have been enrolled on protocol",
                                "criterion": "enrollment of R-PRRT patients",
                                "requirement": {
                                    "requirement_type": "enrollment sequence",
                                    "expected_value": "after 3 PRRT-naïve patients enrolled"
                                }
                            },
                            {
                                "exact_snippets": "minimum progression free survival (PFS) with initial PRRT therapy was ≥ 18 months from day 1, cycle 1 of PRRT to progression",
                                "criterion": "progression free survival (PFS) with initial PRRT therapy",
                                "requirement": {
                                    "requirement_type": "minimum duration",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Patients with unresectable, progressive, histologically well-differentiated neuroendocrine tumors of the fore-, mid-, or hindgut, including pancreas, or those with an unknown primary with target lesions overexpressing somatostatin receptors (Krenning 2, 3 or 4) on a SSTR PET.",
                "criterions": [
                    {
                        "exact_snippets": "unresectable",
                        "criterion": "tumor resectability",
                        "requirement": {
                            "requirement_type": "resectability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "progressive",
                        "criterion": "tumor progression",
                        "requirement": {
                            "requirement_type": "progression_status",
                            "expected_value": "progressive"
                        }
                    },
                    {
                        "exact_snippets": "histologically well-differentiated neuroendocrine tumors",
                        "criterion": "tumor differentiation",
                        "requirement": {
                            "requirement_type": "differentiation",
                            "expected_value": "well-differentiated"
                        }
                    },
                    {
                        "exact_snippets": "neuroendocrine tumors of the fore-, mid-, or hindgut, including pancreas",
                        "criterion": "tumor location",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": [
                                "foregut",
                                "midgut",
                                "hindgut",
                                "pancreas"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "unknown primary with target lesions overexpressing somatostatin receptors (Krenning 2, 3 or 4) on a SSTR PET",
                        "criterion": "somatostatin receptor expression on target lesions",
                        "requirement": {
                            "requirement_type": "overexpression",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "Krenning score"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unknown primary with target lesions overexpressing somatostatin receptors (Krenning 2, 3 or 4) on a SSTR PET",
                        "criterion": "somatostatin receptor expression on target lesions",
                        "requirement": {
                            "requirement_type": "detection_method",
                            "expected_value": "SSTR PET"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "9. Sexually active fertile participants and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Sexually active fertile participants",
                        "criterion": "sexual activity and fertility status",
                        "requirement": {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Sexually active fertile participants",
                        "criterion": "sexual activity and fertility status",
                        "requirement": {
                            "requirement_type": "fertility status",
                            "expected_value": "fertile"
                        }
                    },
                    {
                        "exact_snippets": "must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "medically accepted methods",
                                "barrier methods",
                                "male condom",
                                "female condom",
                                "diaphragm with spermicidal gel"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration of contraception use",
                            "expected_value": "during the course of the study and for 4 months after the last dose of study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Absolute neutrophil count (ANC) ≥ 1500/µL without granulocyte colony-stimulating factor support.",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1500/µL",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/µL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "without granulocyte colony-stimulating factor support",
                        "criterion": "granulocyte colony-stimulating factor support",
                        "requirement": {
                            "requirement_type": "support",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) \u001e 1500/\u00181L",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/\u00181L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "without granulocyte colony-stimulating factor support",
                        "criterion": "granulocyte colony-stimulating factor support",
                        "requirement": {
                            "requirement_type": "support",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Serum albumin ≥ 2.8 g/dl",
                "criterions": [
                    {
                        "exact_snippets": "Serum albumin ≥ 2.8 g/dl",
                        "criterion": "serum albumin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.8,
                                "unit": "g/dl"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum albumin \u0013e 2.8 g/dl",
                        "criterion": "serum albumin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.8,
                                "unit": "g/dl"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Female participants of childbearing potential must not be pregnant at screening. Female participants are considered to be of childbearing potential unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes. In addition, females < 55 years-of-age must have a serum follicle stimulating (FSH) level > 40 mIU/mL to confirm menopause). Note: Documentation may include review of medical records, medical examinations, or medical history interview by study site.",
                "criterions": [
                    {
                        "exact_snippets": "Female participants of childbearing potential must not be pregnant at screening",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Female participants of childbearing potential must not be pregnant at screening",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at screening"
                        }
                    },
                    {
                        "exact_snippets": "Female participants are considered to be of childbearing potential unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy)",
                        "criterion": "permanent sterilization",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Female participants are considered to be of childbearing potential unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy)",
                        "criterion": "permanent sterilization",
                        "requirement": {
                            "requirement_type": "sterilization_procedure",
                            "expected_value": [
                                "hysterectomy",
                                "bilateral salpingectomy",
                                "bilateral oophorectomy"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "documented postmenopausal status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes",
                        "criterion": "postmenopausal status",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "documented postmenopausal status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes",
                        "criterion": "postmenopausal status",
                        "requirement": {
                            "requirement_type": "amenorrhea_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "documented postmenopausal status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes",
                        "criterion": "postmenopausal status",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 45,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "documented postmenopausal status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes",
                        "criterion": "postmenopausal status",
                        "requirement": {
                            "requirement_type": "other_causes",
                            "expected_value": "absence"
                        }
                    },
                    {
                        "exact_snippets": "females < 55 years-of-age must have a serum follicle stimulating (FSH) level > 40 mIU/mL to confirm menopause",
                        "criterion": "serum FSH level",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 55,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "females < 55 years-of-age must have a serum follicle stimulating (FSH) level > 40 mIU/mL to confirm menopause",
                        "criterion": "serum FSH level",
                        "requirement": {
                            "requirement_type": "FSH_level",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mIU/mL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "3. Moderate to severe hepatic impairment (Child-Pugh B or C).",
                "criterions": [
                    {
                        "exact_snippets": "Moderate to severe hepatic impairment (Child-Pugh B or C)",
                        "criterion": "hepatic impairment",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Moderate to severe hepatic impairment (Child-Pugh B or C)",
                        "criterion": "hepatic impairment",
                        "requirement": {
                            "requirement_type": "Child-Pugh classification",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.",
                        "criterion": "systemic anticancer therapy receipt",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.",
                        "criterion": "systemic anticancer therapy receipt",
                        "requirement": {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "cytotoxic",
                                "biologic",
                                "other systemic anticancer therapy",
                                "investigational"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Participants with a diagnosis of incidental, subsegmental PE or DVT within 6 months are allowed if stable, asymptomatic, and treated with a stable dose of permitted anticoagulation (see exclusion criterion #6) for at least 1 week before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "diagnosis of incidental, subsegmental PE or DVT within 6 months",
                        "criterion": "incidental, subsegmental PE or DVT diagnosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "diagnosis of incidental, subsegmental PE or DVT within 6 months",
                        "criterion": "incidental, subsegmental PE or DVT diagnosis",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "if stable, asymptomatic",
                        "criterion": "PE or DVT clinical status",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "if stable, asymptomatic",
                        "criterion": "PE or DVT clinical status",
                        "requirement": {
                            "requirement_type": "symptoms",
                            "expected_value": "asymptomatic"
                        }
                    },
                    {
                        "exact_snippets": "treated with a stable dose of permitted anticoagulation ... for at least 1 week before first dose of study treatment",
                        "criterion": "anticoagulation treatment",
                        "requirement": {
                            "requirement_type": "treatment type",
                            "expected_value": "permitted anticoagulation"
                        }
                    },
                    {
                        "exact_snippets": "treated with a stable dose of permitted anticoagulation ... for at least 1 week before first dose of study treatment",
                        "criterion": "anticoagulation treatment",
                        "requirement": {
                            "requirement_type": "dose stability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "treated with a stable dose of permitted anticoagulation ... for at least 1 week before first dose of study treatment",
                        "criterion": "anticoagulation treatment",
                        "requirement": {
                            "requirement_type": "treatment duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "diagnosis of incidental, subsegmental PE or DVT within 6 months",
                                            "criterion": "incidental, subsegmental PE or DVT diagnosis",
                                            "requirement": {
                                                "requirement_type": "presence",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "exact_snippets": "diagnosis of incidental, subsegmental PE or DVT within 6 months",
                                            "criterion": "incidental, subsegmental PE or DVT diagnosis",
                                            "requirement": {
                                                "requirement_type": "time since diagnosis",
                                                "expected_value": {
                                                    "operator": "<=",
                                                    "value": 6,
                                                    "unit": "months"
                                                }
                                            }
                                        }
                                    ]
                                }
                            ]
                        }
                    },
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "PE or DVT clinical status",
                                    "criterion": "PE or DVT clinical status",
                                    "requirement": {
                                        "requirement_type": "stability",
                                        "expected_value": true
                                    }
                                },
                                {
                                    "exact_snippets": "PE or DVT clinical status",
                                    "criterion": "PE or DVT clinical status",
                                    "requirement": {
                                        "requirement_type": "symptoms",
                                        "expected_value": "asymptomatic"
                                    }
                                },
                                {
                                    "exact_snippets": "treated with a stable dose of permitted anticoagulation ... for at least 1 week before first dose of study treatment",
                                    "criterion": "anticoagulation treatment",
                                    "requirement": {
                                        "requirement_type": "treatment type",
                                        "expected_value": "permitted anticoagulation"
                                    }
                                },
                                {
                                    "exact_snippets": "treated with a stable dose of permitted anticoagulation ... for at least 1 week before first dose of study treatment",
                                    "criterion": "anticoagulation treatment",
                                    "requirement": {
                                        "requirement_type": "dose stability",
                                        "expected_value": true
                                    }
                                },
                                {
                                    "exact_snippets": "treated with a stable dose of permitted anticoagulation ... for at least 1 week before first dose of study treatment",
                                    "criterion": "anticoagulation treatment",
                                    "requirement": {
                                        "requirement_type": "treatment duration",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 1,
                                            "unit": "week"
                                        }
                                    }
                                }
                            ]
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "17. Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.",
                "criterions": [
                    {
                        "exact_snippets": "Any other active malignancy at time of first dose of study treatment",
                        "criterion": "active malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment",
                        "criterion": "malignancy diagnosis within 3 years",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast",
                        "criterion": "locally curable cancers that have been apparently cured (e.g., basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the prostate, cervix, or breast)",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any other active malignancy at time of first dose of study treatment",
                                "criterion": "active malignancy",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast",
                                    "criterion": "locally curable cancers that have been apparently cured (e.g., basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the prostate, cervix, or breast)",
                                    "requirement": {
                                        "requirement_type": "exception",
                                        "expected_value": true
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment",
                                "criterion": "malignancy diagnosis within 3 years",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast",
                                    "criterion": "locally curable cancers that have been apparently cured (e.g., basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the prostate, cervix, or breast)",
                                    "requirement": {
                                        "requirement_type": "exception",
                                        "expected_value": true
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.",
                "criterions": [
                    {
                        "exact_snippets": "Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban",
                        "criterion": "anticoagulation therapy",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "LMWH",
                                "rivaroxaban",
                                "edoxaban",
                                "apixaban"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban",
                        "criterion": "anticoagulation therapy",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": "therapeutic"
                        }
                    },
                    {
                        "exact_snippets": "subjects without known brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment",
                        "criterion": "anticoagulant dose stability",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    },
                    {
                        "exact_snippets": "on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment",
                        "criterion": "anticoagulant dose stability",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor",
                        "criterion": "hemorrhagic complications",
                        "requirement": {
                            "requirement_type": "clinically significant",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "6. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis). Participants must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible participants must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery)",
                        "criterion": "brain metastases or cranial epidural disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery)",
                        "criterion": "brain metastases or cranial epidural disease",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "adequately treated with radiotherapy",
                                "adequately treated with surgery",
                                "adequately treated with radiosurgery"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis)",
                        "criterion": "disease stability after treatment",
                        "requirement": {
                            "requirement_type": "duration of stability",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Participants must have complete wound healing from major surgery or minor surgery before first dose of study treatment",
                        "criterion": "wound healing from surgery",
                        "requirement": {
                            "requirement_type": "completeness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Eligible participants must be neurologically asymptomatic",
                        "criterion": "neurological symptoms",
                        "requirement": {
                            "requirement_type": "asymptomatic",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "without corticosteroid treatment at the time of first dose of study treatment",
                        "criterion": "corticosteroid treatment",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}